Lundbeck Partners with Danish Centre for AI Innovation to Revolutionize Brain Health Research

Lundbeck Collaborates with DCAI to Enhance Brain Health

H. Lundbeck A/S is excited to announce a strategic partnership with the Danish Centre for AI Innovation (DCAI). This collaboration marks a significant step towards revolutionizing drug discovery, particularly in the field of neurological and psychiatric disorders, by leveraging Gefion, Denmark's state-of-the-art AI supercomputer.

Brain disorders pose a substantial challenge, affecting approximately half of the global population and severely limiting quality of life. Despite advancements in medical science, many treatment options remain limited, highlighting the unmet needs in mental health. Lundbeck aims to tackle these challenges by harnessing the unprecedented computational capabilities of Gefion, which promises to speed up the discovery of novel treatments.

With its advanced AI technology, Gefion will provide invaluable insights into molecule discovery and the optimization of drugs, allowing Lundbeck to explore new pathways for the development of therapies. This breakthrough effort will enable researchers not only to enhance existing medical solutions but also to identify and unlock emerging drug targets, providing patients with innovative options for various brain disorders, including rare and specialized conditions.

Tarek Samad, Senior Vice President and Head of Research at Lundbeck, has expressed enthusiasm about this partnership, stating, "We are thrilled to be pioneers in utilizing Gefion's AI supercomputing potential. It represents a crucial opportunity to challenge the existing boundaries in brain disease treatment, aiming to accelerate the development of effective therapies."

Nadia Carlsten, CEO of DCAI, also shared her excitement, emphasizing the significance of this collaboration within the pharmaceutical industry. "Working with a major innovator like Lundbeck not only validates our efforts but also highlights the transformative impact of Gefion's computing power in uncovering new, efficient treatment methods for brain health. It’s a rewarding milestone for us."

Further shedding light on the integration of AI in this partnership, Claus Thomsen, Senior Vice President of Global IT at Lundbeck, highlighted how vital AI is becoming within their strategic framework. "This collaboration signifies a crucial advancement towards redefining brain disease research through AI. By granting our researchers access to Gefion and cutting-edge software, we open new avenues for large-scale simulations and rapid data analysis, significantly benefiting patient care."

This partnership is pivotal as it not only enhances Lundbeck's research capabilities but also sets a precedent for other pharmaceutical companies considering the adoption of AI technologies. The applications of Gefion extend beyond Lundbeck; various organizations are already leveraging its capabilities for AI research, human-centered healthcare solutions, and innovations within the pharmaceutical and biotechnology sectors, thus influencing various industries proactively.

As AI continues to reshape research and innovation landscapes, Gefion is set to play a vital role in addressing global healthcare challenges. Lundbeck and DCAI's partnership exemplifies the game-changing potential of AI supercomputing in yielding significant breakthroughs in medical science and ultimately improving patient outcomes. By embracing this innovative technology, both entities aim to foster a legacy of advanced neuroscience and dedicated care in pharmacotherapy.

About H. Lundbeck A/S

Founded over 70 years ago, Lundbeck is a biopharmaceutical company dedicated exclusively to brain health. With a commitment to resolving the complexities surrounding neurological diseases, the company strives to develop transformative medicines that cater to patients with limited treatment options. By tackling significant neurological challenges, Lundbeck aims to alleviate stigma and enhance health equity globally, driven by a team of approximately 5,500 employees in over 50 countries.

About DCAI

The Danish Centre for AI Innovation operates Gefion, which is recognized as one of the most powerful AI supercomputers globally, designed to facilitate large-scale AI projects across various sectors. Established to lower the barriers to advanced computing, DCAI aims to support innovation and engage customers, including academic researchers and enterprises focused on pioneering efforts in AI.